Background {#Sec1}
==========

Hyponatremia is the most common electrolyte imbalance in hospitalized patients, afflicting at least 30% of patients in medical, surgical and psychiatric wards \[[@CR1], [@CR2]\]. Hyponatremia is a complicated condition that has been associated with all-cause mortality \[[@CR3]\]; length of inpatient stay \[[@CR4]\]; gait and attention impairments \[[@CR5]\]; bone fractures \[[@CR6], [@CR7]\]; and perioperative complications, including 30-day morbidity and mortality \[[@CR8], [@CR9]\]. Most studies that have evaluated the outcomes associated with hyponatremia restricted their analyses to hospitalized patients with pre-existing medical conditions, such as congestive heart failure, chronic kidney disease and liver cirrhosis. Although hypernatremia is also associated with increased mortality, most studies have focused on hyponatremia \[[@CR4]\]. Hyponatremia is common in patients presenting with acute pulmonary embolism \[[@CR10], [@CR11]\], while hypernatremia is associated with increased risk of venous thromboembolism (VTE) \[[@CR12]\]. To date, no study has evaluated the association between hyponatremia and the occurrence of thromboembolic events.

VTE includes both deep vein thrombosis and pulmonary embolism and is a major cause of morbidity and mortality worldwide. Approximately 1 in 1000 adults is affected by VTE annually, with the incidence increasing with age \[[@CR13]\]. VTE ranks third among cardiovascular diseases, preceded only by coronary artery disease and cerebrovascular disease \[[@CR14]\]. The incidence of VTE is increased 100-fold higher in hospitalized patients than in the general population \[[@CR15]\], and VTE is detected in approximately 80% of surgical and medical patients who are not placed on thromboprophylaxis \[[@CR16]\].

Our objective was to perform a population-based retrospective cohort study of patients in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database to evaluate the association between sodium imbalances and the incidence of VTE and other selected perioperative outcomes.

Methods {#Sec2}
=======

Study design and data collection {#Sec3}
--------------------------------

The ACS NSQIP is a nationally validated, outcome-based, risk-adjusted program developed to improve the quality of surgical care for adults in the United States. The program prospectively collects \> 150 variables, including pre- and intraoperative variables and 30-day postoperative mortality and morbidity outcomes for patients undergoing major outpatient or inpatient surgical procedures in more than 200 participating non-Veterans Affairs administration hospitals \[[@CR17], [@CR18]\]. At each hospital site, a trained and certified Surgical Clinical Reviewer (SCR) captures these data using a variety of methods including medical chart abstraction and International Classification of Diseases (ICD) coding. The accuracy of the outcomes of NSQIP dataset are ensured by a host of different training mechanisms for the SCRs and by an Inter-Rater Reliability (IRR) Audit of selected participating sites. Based on the ACS NSQIP participant use files from 2008 to 2012, we identified 1,957,023 adult patients (aged ≥18 years) who underwent major surgery (defined by Current Procedural Terminology codes), No patient was included in the database twice, and only the index case was used for patients who had undergone more than one procedure. We excluded patients who were pregnant and who did not have their sodium levels recorded in their files. Also, due to the high percentages of missing values in a set of confounders, patients with missing values on this set of variables were excluded. A total of 1,108,704 patients were included in the analyses. In accordance with the American University of Beirut's guidelines, which follow the US Code of Federal Regulations for the Protection of Human Subjects, institutional review board approval was not needed or sought for our analysis because the data were collected as part of a quality assurance activity.

Procedures {#Sec4}
----------

Our exposure of interest was the most recent serum sodium measurement within 90 days of surgery. Patients were assigned to one of three groups based on their pre-operative sodium levels. Hyponatremia was defined as sodium \< 135 mEq/L, normal sodium levels were between 135 and 145 mEq/L, and hypernatremia was defined as \> 145 mEq/L. The primary postoperative outcomes were incidences of VTE (defined as the presence of DVT and/or PE during the postoperative period) and 30-day mortality. DVT is currently defined within ACS NSQIP as the "identification of a new blood clot or thrombus within the venous system", which may be coupled with inflammation within 30 days of the operation. This diagnosis is confirmed by a duplex (ultrasound), venogram or CT scan. The patient must be treated with anticoagulation therapy or placement of a vena cava filter or clipping of the vena cava \[[@CR19]\]. PE is defined as "lodging of a blood clot in a pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma". PE is documented if the patient has a V-Q scan interpreted as high probability of PE or a positive CT spiral exam, pulmonary arteriogram or CT angiogram \[[@CR19]\]. 30-day mortality is defined as any cause of death (intraoperative or postoperative) occurring within 30 days of surgery. Secondary outcomes included composite comorbidities (wound, cardiac, respiratory, urinary, central nervous system (CNS), sepsis, bleeding, return to operation room and hospital readmission.

Statistical analysis {#Sec5}
--------------------

Statistical analysis was performed using SAS (SAS version 9.1; SAS, Inc., Cary, NC). *P*-values were 2-sided, and significance was set at 0.05. Baseline demographics and pre-operative and perioperative variables were described for all three categories of blood sodium. Differences were analyzed across categories using the chi-square test for categorical variables and ANOVA for continuous variables. Separate simple and multivariate logistic regression models were used to evaluate the association between blood sodium levels and each outcome. The reference category for the main exposure was set as the normal blood sodium levels. Adjusted odds ratios (ORs) were estimated by including clinically relevant potential confounders of individual outcomes in the models, as outlined in [Appendix](#Sec9){ref-type="sec"}. Stepwise regression was performed at an entry level of 0.15 and a stay level of 0.25. To assess effect modification between sodium and VTE, adjusted ORs were estimated by stratifying for age, sex, surgical specialty, steroid use for chronic conditions, body mass index (BMI), presence of active cancer and chemotherapy.

Results {#Sec6}
=======

For the 1,108,704 patients in this study, the mean age was 57.70 years (SD = 16.69), and 56.2% of patients were female. Sodium levels were normal in 1,010,167 patients, 87,476 had hyponatremia, and 11,061 had hypernatremia. Table [1](#Tab1){ref-type="table"} presents demographics and baseline patient characteristics for each of the sodium groups. Compared with patients with normal sodium levels, patients with hyponatremia and hypernatremia were more likely to be older, inpatients, in a high American Society of Anesthesiologists (ASA) class, exposed to prolonged anesthesia, emergency cases, and under a "do not resuscitate" status. Additionally, these patients were more likely to have partially or totally dependent functional status, have lost more than 10% of their body weight in the prior 6 months, have abnormal pre-operative laboratory studies, and receive perioperative transfusions. Patients with hyponatremia and hypernatremia also had a higher prevalence of dyspnea, diabetes, systemic sepsis, and cardiovascular, respiratory, hepatobiliary, renal, neurological, and hematological-oncological disorders; chronic steroid use; operations within the past month; and infected surgical wounds (Table [1](#Tab1){ref-type="table"}). Patients with normal sodium levels were more likely to be younger than 50 years of age, undergo gynecological, orthopedic, urological and plastic surgeries, have an independent functional status and have a BMI \> 35. Patients with hyponatremia were more likely to be male; have undergone thoracic, vascular and cardiac surgeries; have smoked within 1 year; drink more than two drinks per day; and have a BMI \< 35. Conversely, patients with hypernatremia were more likely to be non-white, have undergone general and otolaryngology surgeries, have undergone general anesthesia and have been in a coma for more than 24 h (Table [1](#Tab1){ref-type="table"}).Table 1Baseline patient characteristics across three categories of blood sodium levelsSodium (mEq/L)\< 135135--145\> 145*p*-value(*n* = 87,476)(*n* = 1,010,167)(*n* = 11,061)Age61.82 ± 16.5257.29 ± 16.6563.38 ± 15.89\< 0.0001  \< 5019,723 (22.6)316,094 (31.3)2015 (18.2)\< 0.0001 50--6426,535 (30.3)330,181 (32.7)3500 (31.6) 65--7927,788 (31.8)271,429 (26.9)3653 (33.0)  ≥ 8013,430 (15.4)92,463 (9.2)1893 (17.1)Sex, female44,389 (50.9)570,528 (56.6)6142 (55.6)\< 0.0001Race, White66,224 (84.8)759,216 (84.6)7777 (78.0)\< 0.0001Surgery type General surgery54,423 (62.2)656,018 (64.9)7529 (68.1)\< 0.0001 Gynecology1503 (1.7)35,143 (3.5)242 (2.2) Neurosurgery2234 (2.6)26,292 (2.6)262 (2.4) Orthopedics6831 (7.8)87,304 (8.6)782 (7.1) Otolaryngology (ENT)922 (1.1)15,953 (1.6)206 (1.9) Plastics615 (0.7)12,522 (1.2)150 (1.4) Thoracic1289 (1.5)10,221 (1.0)128 (1.2) Urology2400 (2.7)39,573 (3.9)361 (3.3) Vascular15,853 (18.1)116,611 (11.5)1317 (11.9) Cardiac surgery1404 (1.6)10,524 (1.0)83 (0.8)Principal anesthesia technique, general80,842 (92.4)929,863 (92.1)10,238 (92.6)\< 0.0001ASA classification I-II25,653 (29.4)512,018 (50.8)3642 (33.0)\< 0.0001 III45,074 (51.7)422,264 (41.9)4666 (42.3) IV-V16,531 (18.9)73,419 (7.3)2721 (24.7)Wound classification, dirty/infected17,210 (19.7)59,804 (5.9)1163 (10.5)\< 0.0001Inpatient status74,600 (85.3)704,245 (69.7)8451 (76.4)\< 0.0001Emergency case25,053 (28.6)123,927 (12.3)2396 (21.7)\< 0.0001Transfusion in 72 h before surgery1992 (2.3)8644 (0.9)643 (5.8)\< 0.0001Do not resuscitate (DNR) status1601 (1.8)6425 (0.6)306 (2.8)\< 0.0001Functional health status before surgery Independent73,530 (84.2)952,051 (94.4)8620 (78.1)\< 0.0001 Partially dependent10,052 (11.5)42,984 (4.3)978 (8.9) Totally dependent3708 (4.3)14,080 (1.4)1439 (13.0)Dyspnea13,284 (15.2)106,592 (10.6)1755 (15.9)\< 0.0001CHF 30 days before surgery2530 (2.9)9234 (0.9)443 (4.0)\< 0.0001History of angina 1 month before surgery1579 (1.8)10,498 (1.0)163 (1.5)\< 0.0001History of MI 6 months before surgery1650 (1.9)7518 (0.7)267 (2.4)\< 0.0001Previous PCI7353 (8.4)61,587 (6.1)881 (8.0)\< 0.0001Previous cardiac surgery8133 (9.3)59,855 (5.9)948 (8.6)\< 0.0001Hypertension requiring medication55,678 (63.7)510,100 (50.5)6682 (60.4)\< 0.0001History of revascularization/amputation for peripheral vascular disease8298 (9.5)40,414 (4.0)580 (5.2)\< 0.0001Smoking within 1 year22,555 (25.8)197,346 (19.5)2045 (18.5)\< 0.0001Current pneumonia1537 (1.8)4815 (0.5)514 (4.7)\< 0.0001History of severe COPD8372 (9.6)52,570 (5.2)967 (8.7)\< 0.0001Ventilator dependent1926 (2.2)7756 (0.8)1193 (10.8)\< 0.0001Ascites2427 (2.8)6325 (0.6)286 (2.6)\< 0.0001Esophageal varices302 (0.4)1017 (0.1)27 (0.2)\< 0.0001Acute renal failure1800 (2.1)5066 (0.5)336 (3.0)\< 0.0001Currently on dialysis4758 (5.4)18,196 (1.8)353 (3.2)\< 0.0001Impaired sensorium2018 (2.3)6524 (0.7)660 (6.0)\< 0.0001Coma \> 24 h136 (0.2)596 (0.1)99 (0.9)\< 0.0001History of transient ischemic attacks (TIA)3662 (4.2)31,358 (3.1)421 (3.8)\< 0.0001CVA/stroke with neurological deficit3432 (3.9)24,497 (2.4)630 (5.7)\< 0.0001CVA/stroke with no neurological deficit2941 (3.4)21,936 (2.2)345 (3.1)\< 0.0001Tumor involving CNS498 (0.6)3703 (0.4)62 (0.6)\< 0.0001Bleeding disorders9989 (11.4)57,672 (5.7)1195 (10.8)\< 0.0001\> 10% loss body weight in previous 6 months4158 (4.8)19,804 (2.0)376 (3.4)\< 0.0001Disseminated cancer3694 (4.2)21,246 (2.1)329 (3.0)\< 0.0001Chemotherapy ≤30 days pre-operative2051 (2.3)14,897 (1.5)239 (2.2)\< 0.0001Radiotherapy in last 90 days1011 (1.2)7705 (0.8)100 (0.9)\< 0.0001BMI28.40 ± 8.1530.31 ± 8.4229.57 ± 8.30\< 0.0001  \< 18.54085 (4.9)20,342 (2.1)343 (3.2)\< 0.0001 18.5--24.927,699 (33.1)249,205 (25.3)2895 (27.3) 25.0--29.924,643 (29.4)300,443 (30.5)3209 (30.3) 30.0--34.913,555 (16.2)192,841 (19.6)2068 (19.5)  ≥ 35.013,716 (16.4)221,151 (22.5)2083 (19.7)Diabetes mellitus with oral agents or insulin23,275 (26.6)167,543 (16.6)2174 (19.7)\< 0.0001Alcohol \> 2 drinks/day 2 wks before admission4925 (5.6)25,735 (2.6)323 (2.9)\< 0.0001Open wound/wound infection11,046 (12.6)43,031 (4.3)1120 (10.1)\< 0.0001Steroid use for chronic condition4717 (5.4)32,860 (3.3)591 (5.3)\< 0.0001Systemic sepsis21,684 (25.0)72,666 (7.3)2411 (21.9)\< 0.0001Prior operation within 30 days6239 (7.1)25,921 (2.6)960 (8.7)\< 0.0001

Thromboembolism occurred in 1.0% of patients in the normal sodium group compared with 1.8% in the hyponatremia group (unadjusted OR 1.89, 95% CI 1.79--2.00) and 2.5% in the hypernatremia group (unadjusted OR 2.64, 95% CI 2.34--2.98) (Table [2](#Tab2){ref-type="table"}). Crude mortality was 1.4% for the normal sodium group compared with 5.1% for the hyponatremia group (unadjusted OR 3.85, 95% CI 3.72--3.98) and 9.2% for the hypernatremia group (unadjusted OR 7.20, 95% CI 6.73--7.69) (Table [2](#Tab2){ref-type="table"}). Crude composite morbidity was 7.3% for the normal sodium group compared with 16.9% for the hyponatremia group (unadjusted OR 2.59, 95% CI 2.54--2.64) and 22.1% for the hypernatremia group (unadjusted OR 3.61, 95% CI 3.45--3.78) (Table [2](#Tab2){ref-type="table"}). Bleeding occurred in 4.3% of patients with normal sodium levels compared with 9.3% in those with hyponatremia (unadjusted OR 2.30, 95% CI 2.24--2.36) and 9.4% in those with hypernatremia (unadjusted OR 2.32, 95% CI 2.18--2.48). Of patients with normal sodium levels, 4.5% had subsequent surgery, and 5.9% were readmitted; by comparison, among patients with hyponatremia, these values were 9.7% (unadjusted OR 2.30, 95% CI 2.25--2.36) and 9.0% (unadjusted OR 1.59, 95% CI 1.52--1.67), respectively; and they were 9.1% (unadjusted OR 2.14, 95% CI 2.00--2.28) and 6.7% (unadjusted OR 1.15, 95% CI 1.00--1.33), respectively, for patients with hypernatremia (Table [2](#Tab2){ref-type="table"}).Table 2Unadjusted analyses for associations between blood sodium levels and outcomesUnadjusted ORsSodium (mEq/L)Sodium (mEq/L)\< 135135--145\> 145\< 135135--145\> 145(*n* = 87,476)(*n* = 1,010,167)(*n* = 11,061)(*n* = 87,476)(*n* = 1,010,167)(*n* = 11,061)Thromboembolism1577 (1.8)9705 (1.0)276 (2.5)1.89 (1.79--2.00)Reference2.64 (2.34--2.98)Mortality4479 (5.1)13,972 (1.4)1014 (9.2)3.85 (3.72--3.98)Reference7.20 (6.73--7.69)Composite morbidity^a^14,795 (16.9)73,563 (7.3)2442 (22.1)2.59 (2.54--2.64)Reference3.61 (3.45--3.78) Wound3908 (4.5)23,316 (2.3)439 (4.0)1.98 (1.91--2.05)Reference1.75 (1.59--1.93) Cardiac1694 (1.9)7472 (0.7)263 (2.4)2.65 (2.51--2.80)Reference3.27 (2.89--3.70) Respiratory7772 (8.9)31,741 (3.1)1639 (14.8)3.01 (2.93--3.08)Reference5.36 (5.08--5.66) Urinary1724 (2.0)7627 (0.8)378 (3.4)2.64 (2.51--2.79)Reference4.65 (4.19--5.17) CNS655 (0.8)3938 (0.4)135 (1.2)1.93 (1.77--2.10)Reference3.16 (2.66--3.75) Sepsis5618 (6.4)25,568 (2.5)870 (7.9)2.64 (2.57--2.72)Reference3.29 (3.06--3.53)Bleeding8128 (9.3)43,090 (4.3)1036 (9.4)2.30 (2.24--2.36)Reference2.32 (2.18--2.48)Return to operation room8490 (9.7)45,091 (4.5)1004 (9.1)2.30 (2.25--2.36)Reference2.14 (2.00--2.28)Readmission (related)^b^2062 (9.0)16,099 (5.9)203 (6.7)1.59 (1.52--1.67)Reference1.15 (1.00--1.33)^a^Composite morbidity considered positive if any of the following are present: wound, cardiac, respiratory, urinary, CNS injury, sepsis or thromboembolism^b^Sample size: 300,815

After adjusting for potential confounders, hyponatremia was significantly and independently associated with an increased risk of thromboembolism (adjusted OR 1.43, 95% CI 1.36--1.52), mortality (adjusted OR 1.39, 95% CI 1.34--1.45), composite morbidity (adjusted OR 2.15, 95% CI 2.11--2.19), major bleeding (adjusted OR 1.96, 95% CI 1.91--2.01), return to operation room (adjusted OR 1.46, 95% CI 1.42--1.50) and readmission (adjusted OR 1.21, 95% CI 1.15--1.27) (Table [3](#Tab3){ref-type="table"}). Hypernatremia was also significantly and independently associated with an increased risk of thromboembolism (adjusted OR 1.57, 95% CI 1.38--1.78), mortality (adjusted OR 1.39, 95% CI 1.27--1.52), composite morbidity (adjusted OR 3.33, 95% CI 3.18--3.49), major bleeding (adjusted OR 2.0, 95% CI 1.87--2.13), and return to operation room (adjusted OR 0.92, 95% CI 0.80--1.06) (Table [3](#Tab3){ref-type="table"}).Table 3Adjusted analyses for associations between blood sodium levels and outcomesSodium (mEq/L)\< 135135--145\> 145(*n* = 87,476)(*n* = 1,010,167)(*n* = 11,061)Thromboembolism1.43 (1.36--1.52)Reference1.57 (1.38--1.78)Mortality1.39 (1.34--1.45)Reference1.39 (1.27--1.51)Composite morbidity^a^2.15 (2.11--2.19)Reference3.33 (3.18--3.49) Wound1.27 (1.22--1.32)Reference1.25 (1.13--1.38) Cardiac1.24 (1.17--1.31)Reference1.38 (1.21--1.57) Respiratory1.77 (1.72--1.82)Reference1.93 (1.80--2.07) Urinary2.28 (2.16--2.40)Reference3.96 (3.56--4.40) CNS1.45 (1.33--1.57)Reference2.25 (1.89--2.68) Sepsis1.72 (1.67--1.78)Reference2.11 (1.96--2.28)Bleeding1.96 (1.91--2.01)Reference2.00 (1.87--2.13)Return to operation room1.46 (1.42--1.50)Reference1.39 (1.30--1.49)Readmission (related)^b^1.21 (1.15--1.27)Reference0.92 (0.80--1.06)^a^Composite morbidity considered positive if any of the following are present: wound, cardiac, respiratory, urinary, CNS injury, sepsis or thromboembolism^b^Sample size: 300,815

The effect of hyponatremia on thromboembolic outcome was evident across all age groups, both sexes, non-orthopedic patients, patients with or without steroid treatment, patients with a BMI \> 18.5, patients with or without cancer and patients with or without chemotherapy (Table [4](#Tab4){ref-type="table"}). The effect of hypernatremia on thromboembolic outcome was evident across all age groups, both sexes, non-orthopedic patients, patients not on steroids, patients with a BMI \> 18.5, patients with or without cancer and patients not receiving chemotherapy (Table [4](#Tab4){ref-type="table"}).Table 4Stratified analyses for associations between blood sodium levels and VTE outcomeSodium (mEq/L)\< 135135--145\> 145(*n* = 87,476)(*n* = 1,010,167)(*n* = 11,061)Thromboembolism1.43 (1.36--1.52)Reference1.57 (1.38--1.78)Age  \< 50 (*n* = 337,832)1.68 (1.45--1.94)Reference1.65 (1.14--2.38) 50--64 (*n* = 360,216)1.65 (1.49--1.83)Reference1.42 (1.11--1.82) 65--79 (*n* = 302,870)1.28 (1.17--1.41)Reference1.67 (1.37--2.03)  ≥ 80 (*n* = 107,786)1.17 (1.02--1.33)Reference1.40 (1.06--1.83)Sex Male (*n* = 484,893)1.37 (1.27--1.48)Reference1.54 (1.29--1.84) Female (*n* = 623,811)1.48 (1.36--1.60)Reference1.57 (1.31--1.88)Surgical specialty Non-orthopedic (*n* = 1,013,787)1.47 (1.39--1.56)Reference1.62 (1.43--1.85) Orthopedic (*n* = 94,917)1.10 (0.89--1.37)Reference0.71 (0.34--1.51)Steroid use for chronic condition No (*n* = 1,070,536)1.45 (1.37--1.54)Reference1.66 (1.46--1.89) Yes (*n* = 38,168)1.26 (1.06--1.51)Reference0.86 (0.53--1.39)BMI  \< 18.5 (*n* = 24,770)1.28 (1.00--1.63)Reference1.68 (0.92--3.07) 18.5--24.9 (*n* = 279,799)1.51 (1.36--1.66)Reference1.52 (1.19--1.95) 25.0--29.9 (*n* = 328,295)1.44 (1.30--1.60)Reference1.50 (1.17--1.93) 30.0--34.9 (*n* = 238,890)1.30 (1.15--1.48)Reference1.45 (1.12--1.89)  ≥ 35.0 (*n* = 236,950)1.52 (1.32--1.74)Reference1.82 (1.39--2.38)Presence of active cancer^a^ No (*n* = 1,068,670)1.42 (1.34--1.51)Reference1.53 (1.34--1.74) Yes (*n* = 40,034)1.25 (1.04--1.49)Reference1.55 (1.29--1.85)Chemotherapy for malignancy ≤30 days pre-surgery No (*n* = 1,091,517)1.42 (1.34--1.51)Reference1.57 (1.38--1.78) Yes (*n* = 17,187)1.67 (1.29--2.16)Reference1.57 (0.79--3.13)^a^Considered positive if any of the following are present: disseminated cancer, tumor involving CNS or chemotherapy for malignancy ≤30 days pre-surgery

The median time from blood draw to surgery was 4 days. Because sodium levels vary over time, we performed a restricted sensitivity analysis for patients in whom blood was drawn within 1 week before surgery. Hyponatremia remained significantly and independently associated with an increased risk of thromboembolism, mortality, composite morbidity, major bleeding, return to operation room and readmission (Table [5](#Tab5){ref-type="table"}). Hypernatremia also remained significantly and independently associated with an increased risk of thromboembolism, mortality, composite morbidity, major bleeding and return to operation room.Table 5Sensitivity analysis of outcomes for Na levels taken ≤7 days prior to surgerySodium (mEq/L)\< 135135--145\> 145(*n* = 71,783)(*n* = 646,416)(*n* = 7795)Thromboembolism1.40 (1.32--1.49)Reference1.66 (1.46--1.89)Mortality1.36 (1.30--1.41)Reference1.40 (1.28--1.53)Composite morbidity^a^2.04 (2.00--2.08)Reference3.86 (3.67--4.06) Wound1.27 (1.22--1.32)Reference1.28 (1.15--1.43) Cardiac1.24 (1.17--1.31)Reference1.42 (1.24--1.62) Respiratory1.67 (1.62--1.72)Reference1.96 (1.82--2.11) Urinary2.07 (1.96--2.19)Reference4.22 (3.78--4.70) CNS1.36 (1.24--1.49)Reference2.34 (1.95--2.81) Sepsis1.65 (1.59--1.70)Reference2.20 (2.04--2.38)Bleeding1.81 (1.76--1.86)Reference2.10 (1.96--2.26)Return to operation room1.43 (1.39--1.47)Reference1.47 (1.37--1.58)Readmission (related)^b^1.19 (1.12--1.25)Reference0.87 (0.73--1.03)^a^Composite morbidity considered positive if any of the following are present: wound, cardiac, respiratory, urinary, CNS injury, sepsis or thromboembolism^b^Sample size: 189,828

Discussion {#Sec7}
==========

In this study, we assessed pre-operative hypo- and hypernatremia in patients across all surgical specialties by analyzing data from the ACS NSQIP database. Hyponatremia and hypernatremia were both significantly and independently associated with postoperative thromboembolism, mortality, morbidity, major bleeding and return to operation room. Only hyponatremia was associated with hospital readmission.

The reported incidence of hyponatremia upon hospital admission ranges from 5 to 30% depending on the study population and timing of serum sodium measurements \[[@CR20]--[@CR23]\]. We report a 7.89% rate of pre-operative hyponatremia among surgical patients. Hyponatremia has been associated with increased mortality in patients with pre-existing acute kidney injury \[[@CR24]\], chronic kidney disease \[[@CR25]\], heart failure \[[@CR26]--[@CR29]\], COPD \[[@CR30]\], hip fractures \[[@CR31]\], and intracerebral hemorrhage \[[@CR32]\]; in patients undergoing cardiac transplantation \[[@CR33]\]; and in unselected inpatients with hyponatremia \[[@CR9], [@CR34], [@CR35]\]. The reported mortality rate ranges from 5.2 to 22% \[[@CR8], [@CR21], [@CR22], [@CR34], [@CR36]\]. Our study had a 5.12% mortality rate among hyponatremic patients, similar to that reported by Leung et al. (5.2%), Waikar et al. (5.4%) and Zilberger et al. (5.9%). However, our mortality rate was lower than that reported by Holland-Bill et al. (8.1%) and much lower than that reported by Sturdik et al. (22%). The higher mortality rates reported by Holland-Bill et al. and Sturdik et al. may be related to their study populations, which included patients who were admitted to the internal medicine department. In contrast, our study population and that of Leung et al. involved surgical patients, and studies by Zilberberg et al. and Waiker et al. included a more general patient population. Increased morbidity \[[@CR8], [@CR28], [@CR30]\] and 30-day hospital readmissions \[[@CR26], [@CR37]\] have also been reported in patients with hyponatremia. Hyponatremia is a common finding among patients with pulmonary embolism, occurring at rates ranging from 21 to 26% \[[@CR10], [@CR11]\]. In their meta-analysis, Zhou XY et al. reported that in-hospital mortality was 12.9% in hyponatremic patients with pulmonary embolism and 2.3% in normonatremic patients. The mean 30-day mortality was 15.9% in the hyponatremia group and was 7.4% in the normonatremia group \[[@CR38]\]. However, no study has evaluated the direct association between hyponatremia and the development of pulmonary embolism or deep vein thrombosis.

Similar to hyponatremia, hypernatremia was associated with increased mortality in patients undergoing percutaneous endoscopic gastrostomy \[[@CR39]\], cardiothoracic surgery \[[@CR40]\], or cardiac transplantation; in hip fracture patients \[[@CR31]\]; in patients with chronic kidney disease \[[@CR25]\]; in critically ill patients \[[@CR41]--[@CR43]\]; and in patients with traumatic brain injuries \[[@CR33], [@CR44]\]. The reported mortality rate varies greatly, ranging from as low as 5.2% to as high as 82% \[[@CR45]--[@CR54]\]. This discrepancy is mainly due to data from elderly patients \[[@CR46], [@CR47], [@CR49], [@CR50]\] and on which cutoff value is used to define hypernatremia \[[@CR51]--[@CR54]\]. However, using a study population similar to ours, Leung et al. reported hypernatremia in 2.2% of surgical patients compared with 1% in our population and a mortality rate of 5.2%, which is close to our 9.16% mortality rate \[[@CR12]\]. The authors similarly reported that hypernatremia predicted the occurrence of perioperative major coronary events, pneumonia, and VTE \[[@CR12]\]. Our analysis was extended to evaluate the association of both hyponatremia and hypernatremia with the occurrence of thromboembolic events.

Postoperative thromboembolism within a time frame of 30 days occurred in 2.49% of patients with hypernatremia and 1.8% of patients with hyponatremia. Leung et al. reported thromboembolism among 1.8% of hypernatremic patients \[[@CR12]\]. We found that the effect of hyponatremia on thromboembolic outcome was evident across all age groups, both sexes, patients with or without steroid treatment, patients with a BMI \> 18.5, patients with or without cancer and patients with or without chemotherapy. However, hyponatremia was not associated with thromboembolic events in orthopedic patients. The effect of hypernatremia on thromboembolic outcome was also evident across all age groups, both sexes, patients with a BMI \> 18.5, and patients with or without cancer. However, hypernatremic patients undergoing orthopedic surgery and patients on chemotherapy and steroids did not develop thromboembolisms. VTE is a serious complication following major orthopedic surgery, and all patients undergoing orthopedic surgery receive thromboprophylaxis with a pharmacological agent or Intermittent Pneumatic Compression Device (IPCD) for a minimum of 10 to 14 days, sometimes extending prophylaxis up to 35 days \[[@CR55]\]. This prophylaxis could explain why hyponatremic and hypernatremic patients undergoing orthopedic surgery were not at risk of developing VTE. Systemic glucocorticoid use increases the risk of VTE among present, new, continuing and recent users but not among former users \[[@CR56]\]. Corticosteroid therapy is associated with a nearly 5-fold increase in the risk of VTE \[[@CR57]\]. Surgical patients with prolonged pre-operative glucocorticoid intake are at a higher risk of developing postoperative VTE and secondary outcomes, including all-cause mortality, urinary tract complications sepsis, wound occurrences, cardiac and respiratory adverse events \[[@CR58]\]. This observation suggests that hyponatremic and hypernatremic patients on steroids are at risk for VTE. However, hypernatremic patients on steroids did not show an increased risk of VTE in our study. Hypernatremia is sometimes encountered in patients with hypertension secondary to aldosteronism \[[@CR59]\]. Medical treatment involves the use spironolactone (aldosterone antagonist or Amiloride) in addition to angiotensin-converting enzyme inhibitors for better control of blood pressure \[[@CR60]\]. Chae et al. recently reported that after controlling for factors related to VTE, the use of renin-angiotensin inhibitors was still associated with a significantly lower risk of developing VTE \[[@CR61]\], which may explain why hypernatremic patients in our study receiving steroids were protected against VTE.

Chemotherapy use in cancer patients increases the risk of VTE 6.5-fold compared with non-cancer patients \[[@CR62]\]. Salahudeen et al. recently reported that 90% of hypernatremia cases among cancer patients are hospital acquired and largely involve leukemia and stem cell transplant patients. The authors also found that, compared with patients with normo- or hyponatremia, patients with hypernatremia were extremely sick and frequently admitted to critical care units \[[@CR63]\]. Our results reveal that hypernatremic patients receiving chemotherapy were not at risk of developing VTE, which may be attributed to this high-risk population receiving thromboprophylaxis treatment. The guidelines on VTE prevention in oncology from the United States National Comprehensive Cancer Network \[[@CR64], [@CR65]\] and the American Society of Clinical Oncology \[[@CR66]\] suggest that thromboprophylaxis should be considered for high-risk ambulatory patients with cancer who receive chemotherapy.

The limitations of this work include a current shortage of biological data on the plausibility of the link between hypernatremia and postoperative thromboembolism. The association between hyponatremia and pulmonary embolism has been established. However, this association has not been established for deep vein thrombosis. Second, in the ACS NSQIP database, only one pre-operative serum sodium value is available and there was large variability in the collection and timing of preoperative blood work. However, sensitivity analyses suggested that risks were similar in patients with sodium measurements taken within 1 week of surgery. Third, patients are followed after surgery for 30 days thus omplications or death after that period are not included. Fourth, around 260,123 (19.0%) individuals out of 1,368,827 were excluded due to missing values on sodium levels. This selection bias has not been accounted for in this study.. Fifth, patients with severe cases of both hyponatremia and hypernatremia likely received some form of treatment. Thus, the incidence of hyponatremia and hypernatremia reported in our study may not be representative of the rates on the day of surgery. Finally, since this study aims at studying causality between sodium imbalances and VTE using a large retrospective dataset, much confounding remains unaddressed despite our careful adjustment for many clinically and statistically relevant factors. For instance, we cannot exclude the possibility of unmeasured confounding factors such as the use of diuretics and DVT prophylaxis, which is unavailable in the ACS NSQIP database analyzed. Thus, it is still not clear whether the associations between both hyponatremia and hypernatremia and increased risk of VTE, morbidity and mortality are due to the adverse effects of sodium imbalances or the underlying diseases. Future work needs to be performed to establish whether sodium imbalance is in fact a causal factor for post-operative VTE.

Conclusion {#Sec8}
==========

Our results reveal an increased VTE risk, as well as increased mortality and morbidity, in both hyponatremic and hypernatremic patients. Because sodium levels are routinely measured in hospitalized patients, they could be easily utilized in identifying patients at risk of developing VTE. Recent evidence suggests that an improvement in serum sodium in hyponatremic patients is associated with a reduction of overall mortality \[[@CR67]\]. Thus, hypernatremia and hyponatremia in surgical patients should not be ignored and patients with sodium imbalances ought to be more closely monitored for potential complications after surgery.

Appendix {#Sec9}
========

Table 6Clinically relevant potential confoundersVTEMortalityWoundCardiacRespiratoryUrinaryCNSSepsisBleedingComposite MorbidityReturn ORReadmissionAgeXXXXXXXGenderXRaceXType of AnesthesiaXXXASA ClassXXXXXInfected Surgical Wound ClassXXXXMean Total Operation Time minXIntraop TransfusionsXXXXXXCHF w/in 30 daysXXXXXMI w/in 6 monthsXXXHistory of anginaXXTobacco use in past yearXXXXXxHistory of severe COPDXXxXEsophageal varices in previous 6 monthsXXxAcute renal failureXXCurrently on dialysisXXXXXXXImpaired sensorium in previous 48 hXXHemiplegiaXXHistory of transient ischemic attacksXXHistory of CVA with neurological deficitXXXXHistory of CVA without neurological deficitXTumor involving CNSXXXBleeding disorderXXXXWeight loss \> 10% in previous 6 monthsXDisseminated cancerXXXXXXXChemotherapy in previous 30 daysXBMIXXXXXXXXDiabetic on oral drugs or insulinXXXXXXXHypertension requiring medsXXXPeripheral vascular diseaseXXRest pain or gangreneXXXOpen wound (with or without infection)XXXXSteroid use for chronic conditionXXSystemic sepsis in previous 48 hXWBC countXPlatelet countXXXINRXCreatinineXSerum albuminXEmergency caseXXXSurgical SpecialtyXXDyspneaXXFunctional health status Prior to SurgeryXXVentilator dependentXXCurrent pneumoniaXXXComa \> 24 hXXParaplegiaXQuadraplegiaXBilirubinXHematocritXXPTTXDuration of AnesthesiaXXX

ACS NSQIP

:   American College of Surgeons National Surgical Quality Improvement Program

ASA

:   American Society of Anesthesiologists

BMI

:   Body mass index

CNS

:   Central nervous system

ICD

:   International Classification of Diseases

IPCD

:   Intermittent pneumatic compression device

SCR

:   Surgical Clinical Reviewer

VTE

:   Venous thromboembolism
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